Longeveron Will Attend Three Investment Conferences
The Miami-based firm will present its aging-related research at upcoming forums this October.
Updated on Sept. 30, 2026 in Alzheimer’s
Live Poll
Is now a good time for individual investors to support emerging longevity-focused biotech companies?
In October 2026, Miami-based Longeveron will participate in three major investment conferences to discuss its research into aging and Alzheimer’s disease. This push for new funding follows the company receiving a $1,000,000 Milestone 2 Award from the XPRIZE Healthspan competition.
Why it matters
Longeveron is seeking additional capital to advance its development of laromestrocel, an investigational product derived from donor bone marrow cells. The company aims to secure revenue to continue testing whether the therapy can reduce neuroinflammation in patients.
A Phase 2a trial of 49 participants used free water MRI imaging to evaluate neuroinflammation. The investigational product laromestrocel remains unapproved by the FDA.
The players
Longeveron
This Miami-based biotechnology company specializes in developing cellular therapies for aging-related and chronic diseases.
XPRIZE
This non-profit organization hosts global competitions aimed at incentivizing technological breakthroughs and research innovation.
The details
The firm recently published a preprint manuscript on medRxiv detailing its Phase 2a data, which suggests potential benefits for protecting brain tissue. Longeveron is also competing for an XPRIZE Grand Prize of up to $81 million after being selected as a finalist.
Timeline
October 1-3, 2026: Longeveron attends the Aging Research and Drug Discovery Meeting in Boston.
October 7-11, 2026: The company participates in the Abundance Longevity Trip.
October 19-20, 2026: Representatives will attend the Longevity Partnering Forum in South San Francisco.
Deeper Dive
Longeveron's participation in the XPRIZE Healthspan competition aligns with a broader industry move toward incentive-based funding for aging research. This strategy positions the company within a cohort of 600 initial applicants vying to address the challenges of age-related cognitive decline.
While laromestrocel is currently investigational and unavailable to the public, the research highlights potential future pathways for managing neuroinflammation. Patients should follow official clinical trial registries to monitor the status of this product.
The takeaway
Longeveron is actively leveraging its clinical trial findings to secure the capital needed to advance its stem cell-based therapies. The firm's performance in the coming months may determine its ability to scale research into potential treatments for cognitive decline.
What happens next
Longeveron is scheduled to participate in the Aging Research and Drug Discovery Meeting from October 1-3, 2026, followed by the Abundance Longevity Trip and the Longevity Partnering Forum later in the month.
Further reading
For more information, see our Alzheimer’s section.
More information
Read the complete full preprint manuscript on the medRxiv platform.
Live Poll
Is now a good time for individual investors to support emerging longevity-focused biotech companies?
